199 related articles for article (PubMed ID: 16418574)
1. Promoter hypermethylation of FANCF plays an important role in the occurrence of ovarian cancer through disrupting Fanconi anemia-BRCA pathway.
Wang Z; Li M; Lu S; Zhang Y; Wang H
Cancer Biol Ther; 2006 Mar; 5(3):256-60. PubMed ID: 16418574
[TBL] [Abstract][Full Text] [Related]
2. Promoter Hypermethylation of FANCF and Susceptibility and Prognosis of Epithelial Ovarian Cancer.
Ding JJ; Wang G; Shi WX; Zhou HH; Zhao EF
Reprod Sci; 2016 Jan; 23(1):24-30. PubMed ID: 26507869
[TBL] [Abstract][Full Text] [Related]
3. Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer.
Narayan G; Arias-Pulido H; Nandula SV; Basso K; Sugirtharaj DD; Vargas H; Mansukhani M; Villella J; Meyer L; Schneider A; Gissmann L; Dürst M; Pothuri B; Murty VV
Cancer Res; 2004 May; 64(9):2994-7. PubMed ID: 15126331
[TBL] [Abstract][Full Text] [Related]
4. Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer.
Lim SL; Smith P; Syed N; Coens C; Wong H; van der Burg M; Szlosarek P; Crook T; Green JA
Br J Cancer; 2008 Apr; 98(8):1452-6. PubMed ID: 18414472
[TBL] [Abstract][Full Text] [Related]
5. RNA interference-mediated FANCF silencing sensitizes OVCAR3 ovarian cancer cells to adriamycin through increased adriamycin-induced apoptosis dependent on JNK activation.
He M; Sun HG; Hao JY; Li YL; Yu JK; Yan YY; Zhao L; Li N; Wang Y; Bai XF; Yu ZJ; Zheng ZH; Mi XY; Wang EH; Wei MJ
Oncol Rep; 2013 May; 29(5):1721-9. PubMed ID: 23440494
[TBL] [Abstract][Full Text] [Related]
6. [Disfigurement of p16INK4A gene expression in development of ovarian cancer and the mechanism].
Li M; Huang ZJ; Dong WH; Li XY; Wang XY; He XH; Wang H; Wang ZH
Zhonghua Fu Chan Ke Za Zhi; 2006 Jun; 41(6):408-12. PubMed ID: 16831366
[TBL] [Abstract][Full Text] [Related]
7. Low incidence of methylation of the promoter region of the FANCF gene in Japanese primary breast cancer.
Tokunaga E; Okada S; Kitao H; Shiotani S; Saeki H; Endo K; Morita M; Kakeji Y; Maehara Y
Breast Cancer; 2011 Apr; 18(2):120-3. PubMed ID: 19813073
[TBL] [Abstract][Full Text] [Related]
8. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors.
Taniguchi T; Tischkowitz M; Ameziane N; Hodgson SV; Mathew CG; Joenje H; Mok SC; D'Andrea AD
Nat Med; 2003 May; 9(5):568-74. PubMed ID: 12692539
[TBL] [Abstract][Full Text] [Related]
9. Gene silencing of FANCF potentiates the sensitivity to mitoxantrone through activation of JNK and p38 signal pathways in breast cancer cells.
Li Y; Zhao L; Sun H; Yu J; Li N; Liang J; Wang Y; He M; Bai X; Yu Z; Zheng Z; Mi X; Wang E; Wei M
PLoS One; 2012; 7(8):e44254. PubMed ID: 22952942
[TBL] [Abstract][Full Text] [Related]
10. The Fanconi Anemia/BRCA signaling pathway: disruption in cisplatin-sensitive ovarian cancers.
D'Andrea AD
Cell Cycle; 2003; 2(4):290-2. PubMed ID: 12851475
[TBL] [Abstract][Full Text] [Related]
11. [Effects of 5-Aza-2'-deoxycytidine and trichostatin A on DNA methylation and expression of hMLH1 in ovarian cancer cell line COC1/DDP].
Meng CF; Dai DQ; Guo KJ
Ai Zheng; 2008 Dec; 27(12):1251-5. PubMed ID: 19079988
[TBL] [Abstract][Full Text] [Related]
12. Expression and promoter methylation status of mismatch repair gene hMLH1 and hMSH2 in epithelial ovarian cancer.
Zhang H; Zhang S; Cui J; Zhang A; Shen L; Yu H
Aust N Z J Obstet Gynaecol; 2008 Oct; 48(5):505-9. PubMed ID: 19032668
[TBL] [Abstract][Full Text] [Related]
13. FANCF methylation contributes to chemoselectivity in ovarian cancer.
Olopade OI; Wei M
Cancer Cell; 2003 May; 3(5):417-20. PubMed ID: 12781358
[TBL] [Abstract][Full Text] [Related]
14. Curcumin causes promoter hypomethylation and increased expression of FANCF gene in SiHa cell line.
Parashar G; Parashar NC; Capalash N
Mol Cell Biochem; 2012 Jun; 365(1-2):29-35. PubMed ID: 22297615
[TBL] [Abstract][Full Text] [Related]
15. Function of the Fanconi anemia pathway in Fanconi anemia complementation group F and D1 cells.
Siddique MA; Nakanishi K; Taniguchi T; Grompe M; D'Andrea AD
Exp Hematol; 2001 Dec; 29(12):1448-55. PubMed ID: 11750104
[TBL] [Abstract][Full Text] [Related]
16. Aberrant promoter methylation of SPARC in ovarian cancer.
Socha MJ; Said N; Dai Y; Kwong J; Ramalingam P; Trieu V; Desai N; Mok SC; Motamed K
Neoplasia; 2009 Feb; 11(2):126-35. PubMed ID: 19177197
[TBL] [Abstract][Full Text] [Related]
17. Estrogen receptor alpha, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers.
Wei M; Xu J; Dignam J; Nanda R; Sveen L; Fackenthal J; Grushko TA; Olopade OI
Breast Cancer Res Treat; 2008 Sep; 111(1):113-20. PubMed ID: 17932744
[TBL] [Abstract][Full Text] [Related]
18. Fancf-deficient mice are prone to develop ovarian tumours.
Bakker ST; van de Vrugt HJ; Visser JA; Delzenne-Goette E; van der Wal A; Berns MA; van de Ven M; Oostra AB; de Vries S; Kramer P; Arwert F; van der Valk M; de Winter JP; te Riele H
J Pathol; 2012 Jan; 226(1):28-39. PubMed ID: 21915857
[TBL] [Abstract][Full Text] [Related]
19. Promoter hypermethylation influences the suppressive role of maternally expressed 3, a long non-coding RNA, in the development of epithelial ovarian cancer.
Sheng X; Li J; Yang L; Chen Z; Zhao Q; Tan L; Zhou Y; Li J
Oncol Rep; 2014 Jul; 32(1):277-85. PubMed ID: 24859196
[TBL] [Abstract][Full Text] [Related]
20. Methylation-associated silencing of death-associated protein kinase gene in laryngeal squamous cell cancer.
Kong WJ; Zhang S; Guo C; Zhang S; Wang Y; Zhang D
Laryngoscope; 2005 Aug; 115(8):1395-401. PubMed ID: 16094112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
